| Human Molecular Genetics | Pages |
A genetic polymorphism of the peroxisome proliferator-activated receptor [gamma] gene influences plasma leptin levels in obese humans
Introduction
Results
Discussion
Materials And Methods
Population study
Biological measurements
Genetic analysis
Statistical analysis
Abbreviations
Acknowledgements
References
A genetic polymorphism of the peroxisome proliferator-activated receptor [gamma] gene influences plasma leptin levels in obese humans
Peroxisome proliferator-activated receptor [gamma] (PPAR[gamma]) is a transcription factor implicated in adipocyte differentiation, lipid and glucose metabolism. A polymorphism corresponding to a silent C[rarr]T substitution was detected in exon 6 of the PPAR[gamma] gene. We analysed the relationships between this genetic polymorphism and various markers of the obesity phenotype (body weight, body mass index, waist:hip ratio and plasma leptin levels) in a representative sample of 820 men and women living in northern France. The frequencies of the C and T alleles were 0.860 and 0.140 respectively. In the whole sample no association of the polymorphism with the markers tested was observed but a statistically significant interaction (P < 0.03) existed between this polymorphism and body mass index for plasma leptin levels. This result suggested that the impact of the PPAR[gamma] gene polymorphism on plasma leptin levels differed according to the BMI of the subjects. Indeed, obese subjects (BMI > 30 kg/m2) bearing at least one T allele (CT+TT) had higher plasma leptin levels than subjects who did not (35.0 ± 17.4 ng/ml versus 28.3 ± 14.8 ng/ml respectively; P < 0.001). This effect existed in both genders, despite the higher plasma leptin levels observed in women. The plasma leptin level increase was not associated with elevation of body mass index, even though these two variables were highly correlated. Thus for a given leptin level the BMI was relatively lower in obese subjects carrying at least one T allele than in obese CC homozygotes. Our results show that in obese subjects variability within the PPAR[gamma] gene locus is associated with circulating leptin levels and may modify the relationship between leptin levels and adipose tissue mass.
INTRODUCTION
Obesity is a complex metabolic disorder with strong genetic components (1). Candidate genes are numerous and may involve both structural and regulatory proteins from various tissues. Peroxisome proliferator-activated receptor [gamma] (PPAR[gamma]) is a member of the nuclear hormone receptor superfamily and is secreted in adipose tissue. PPAR[gamma] controls adipocyte differentiation (2-4) and regulates lipid and glucose homeostasis (reviewed in 5,6). For instance, in animal models and in in vitro cell culture systems PPAR[gamma] enhances expression of genes such as lipoprotein lipase (7), aP2 (8), phosphoenolpyruvate carboxykinase (9) and acylCoA synthase (10), while it down-regulates expression of the leptin gene (11-14). Recently thiazolidinediones were shown to bind PPAR[gamma] with high affinity, offering a clue to the biological efficiency of these antidiabetic drugs (3,15). Therefore, because of its pleiotropic role in glucose and lipid metabolism, PPAR[gamma] is clearly a candidate gene for regulation of adipose tissue metabolism in humans.
The PPAR[gamma] gene has been cloned and characterized (16). Recently we identified a frequent polymorphism located in exon 6. This polymorphism results from a silent C[rarr]T substitution at nt 161 (C/T exon 6 PPAR[gamma]). Because of the link between PPAR[gamma] and adipocyte metabolism, we hypothesized that variability at the genetic locus of PPAR[gamma] might be associated with variability of adipose tissue phenotype. We used the C/T exon 6 PPAR[gamma] polymorphism as a marker to detect possible relationships between PPAR[gamma] and several clinical and biological variables related to adipose tissue mass, such as leptin. Leptin, a 167 amino acid protein secreted by adipocytes (17), exerts some of its effects in the brain (arcuate nucleus), where specific receptors have been identified (18). Basal concentrations of leptin in the bloodstream are proportional to adipose tissue mass and hence leptin level is a good marker of adipose tissue size (19-22).
RESULTS
In the 1154 subjects characterized, including 585 men and 569 women, the genotypic distribution of the C/T exon 6 PPAR[gamma] polymorphism was in Hardy-Weinberg equilibrium (CC, 73.9%; CT, 24.5%; TT, 1.6%). Allelic frequencies were 0.867 for the wild-type C allele and 0.133 for the rare T allele. The genotypic and allelic frequencies were similar in men and women. Because of interference by a number of metabolic disorders and treatments with blood variables, individuals treated for dyslipidemia, hypertension or diabetes mellitus were excluded from the analyses. This resulted in a sample of 820 individuals (404 men, 416 women). The allelic and genotypic frequencies of this subsample were not different from those of the entire group (0.860 and 0.140 for the C and T alleles respectively). In order to increase the statistical power of the analyses the sample was divided in two subgroups: subjects bearing at least one T allele (CT+TT) and subjects without the T allele (CC). After adjustment for confounding factors (age, gender, alcohol consumption and smoking) no association between the C/T exon 6 PPAR[gamma] polymorphism and any of the anthropometric and biological variables was found. There was no statistically significant interaction between the C/T exon 6 PPAR[gamma] polymorphism and gender or age for any variables. The distributions of these variables according to 10 year age classes for the whole and for the non-treated subjects are presented in Table 1.
Since PPAR[gamma] plays an essential role in adipocyte differentiation, we analysed whether the relationships between the C/T PPAR[gamma] polymorphism and biological variables could be influenced by BMI. Indeed, there was a statistically significant interaction (P < 0.03) between the C/T exon 6 PPAR[gamma] polymorphism and BMI (introduced in the model as a quantitative variable) for plasma leptin levels (Fig. 1). Thus we examined the effect of the polymorphism on plasma leptin levels in obese and non-obese subjects separately, according to the WHO criteria of obesity (BMI > 30 kg/m2) (23; Table 2). The C/T exon 6 PPAR[gamma] allelic frequencies were similar in obese (C, 0.849; T, 0.151) and non-obese individuals (C, 0.862; T, 0.138).
Table 1
| Whole population (n = 1154) | Non-treated subjects (n = 820) | |||||||
| 35-44 years (n = 388) |
45-54 years (n = 386) |
55-64 years (n = 380) |
P valuea | 35-44 years (n = 340) |
45-54 years (n = 280) |
55-64 years (n = 200) |
P valuea | |
| Weight (kg) | 73.3 ± 15.5 | 74.7 ± 15.2 | 74.9 ± 14.9 | 0.31 | 72.4 ± 15.2 | 72.5 ± 14.3[setmn] | 72.0 ± 14.6 | 0.9 |
| Waist:hip ratio | 0.86 ± 0.09 | 0.89 ± 0.09 | 0.91 ± 0.10 | 0.0001 | 0.85 ± 0.09 | 0.87 ± 0.09 | 0.89 ± 0.10 | 0.0001 |
| BMI (kg/m2) | 25.6 ± 4.7 | 26.8 ± 5.2 | 27.4 ± 4.9 | 0.0001 | 25.3 ± 4.6 | 25.9 ± 4.4 | 26.1 ± 4.2 | 0.1 |
| Leptin (ng/ml)b | 14.60 ± 13.02 | 16.53 ± 13.14 | 18.33 ± 13.7 | 0.0001 | 14.24 ± 12.96 | 15.28 ± 12.04 | 16.41 ± 12.73 | 0.03 |
| Leptin:BMI ratiob | 0.54 ± 0.41 | 0.59 ± 0.40 | 0.64 ± 0.43 | 0.05 | 0.53 ± 0.41 | 0.57 ± 0.40 | 0.60 ± 0.43 | 0.15 |
| Glucose (mmol/l)b | 5.27 ± 1.27 | 5.55 ± 1.42 | 5.85 ± 1.78 | 0.0001 | 5.09 ± 0.68 | 5.29 ± 0.80 | 5.43 ± 1.26 | 0.0001 |
| Insulin (µU/ml)b | 15.42 ± 10.72 | 15.97 ± 10.58 | 16.70 ± 10.82 | 0.23 | 13.88 ± 7.14 | 14.03 ± 7.77 | 14.40 ± 8.39 | 0.9 |
| Total cholesterol (mmol/l) | 5.61 ± 0.97 | 5.92 ± 1.03 | 6.17 ± 1.16 | 0.0001 | 5.58 ± 0.97 | 5.90 ± 1.05 | 6.13 ± 1.02 | 0.0001 |
| Triglycerides (mmol/l)b | 1.41 ± 1.29 | 1.49 ± 1.39 | 1.38 ± 0.89 | 0.33 | 1.37 ± 1.31 | 1.39 ± 1.35 | 1.24 ± 0.84 | 0.9 |
| Systolic blood pressure (mm Hg) | 124.7 ± 14.8 | 134.4 ± 19.2 | 141.9 ± 20.0 | 0.0001 | 123.6 ± 14.6 | 131.0 ± 17.5 | 137.9 ± 19.3 | 0.0001 |
| Diastolic blood pressure (mm Hg) | 80.1 ± 10.7 | 84.6 ± 12.0 | 84.3 ± 11.3 | 0.0001 | 79.4 ± 10.6 | 82.6 ± 11.3 | 83.0 ± 11.4 | 0.0001 |
Table 2
| Non-obese subjects (BMI [le] 30 kg/m2; n = 703) | NObese subjects (BMI > 30 kg/m2; n = 116) | |||||
| CC (n = 520) | CT+TT (n = 183) | P | CC (n = 82) | CT+TT (n = 34) | P | |
| Weight (kg) | 68.3 ± 11.9 | 70.4 ± 11.5 | ns | 93.4 ± 12.5 | 93.7 ± 12.6 | ns |
| Waist:hip ratio | 0.86 ± 0.09 | 0.87 ± 0.09 | ns | 0.92 ± 0.09 | 0.92 ± 0.09 | ns |
| BMI (kg/m2) | 24.2 ± 2.9 | 24.6 ± 2.7 | ns | 34.0 ± 3.2 | 34.0 ± 3.6 | ns |
| Leptin (ng/ml)a | 12.9 ± 10.3 | 11.8 ± 9.3 | ns | 28.3 ± 14.8 | 35.0 ± 17.4 | 0.001 |
| Leptin:BMI ratioa | 0.52 ± 0.39 | 0.47 ± 0.36 | ns | 0.82 ± 0.42 | 1.02 ± 0.48 | 0.007 |
| Glucose (mmol/l)a | 5.15 ± 0.66 | 5.17 ± 0.71 | ns | 5.76 ± 1.24 | 5.89 ± 2.39 | ns |
| Insulin (µU/ml)a | 13.1 ± 7.86 | 13.5 ± 6.89 | ns | 23.27 ± 15.07 | 19.3 ± 7.44 | ns |
| Total cholesterol (mmol/l) | 5.77 ± 1.02 | 5.95 ± 1.05 | ns | 5.80 ± 1.07 | 5.92 ± 1.09 | ns |
| Triglycerides (mmol/l)a | 1.34 ± 1.99 | 1.48 ± 2.12 | ns | 1.70 ± 1.14 | 1.57 ± 0.97 | ns |
| Systolic blood pressure (mm Hg) | 128.5 ± 17.9 | 128.5 ± 16.2 | ns | 136.3 ± 18.6 | 136.3 ± 16.7 | ns |
| Diastolic blood pressure (mm Hg) | 80.2 ± 10.9 | 80.8 ± 10.4 | ns | 88.1 ± 12.0 | 86.0 ± 9.2 | ns |
Figure
As expected, obese subjects (n = 116) had higher plasma leptin levels than non-obese subjects (n = 703) (30.2 ± 15.8 ng/ml versus 12.6 ± 10.0 ng/ml respectively; P < 0.0001). In obese subjects multivariate analysis adjusted for confounding factors (age, gender, BMI, plasma insulin levels, alcohol consumption and smoking) revealed a statistically significant difference in leptin levels between genotypes (35.0 ± 17.4 ng/ml for CT+TT versus 28.3 ± 14.8 ng/ml for CC; P < 0.001) (Fig. 2). There were no statistically significant differences for BMI (Fig. 2) (34.0 ± 3.6 ng/ml for CT+TT versus 34.0 ± 3.2 ng/ml for CC), waist:hip ratio or body weight between CC subjects and T allele bearers. Moreover, the leptin:BMI ratio was statistically different according to genotype (1.02 ± 0.48 for CT+TT versus 0.82 ± 0.42 for CC; P < 0.007) (Table 2). There were no other statistically significant differences in clinical and biological variables according to the C/T exon 6 PPAR[gamma] polymorphism. No statistically significant difference was found in the non-obese group.
Figure
Finally, since plasma leptin levels differ significantly between men and women, we compared association of the C/T exon 6 PPAR[gamma] polymorphism in obese men (n = 51) and women (n = 65) separately (Fig. 3). As expected, in our population women exhibited higher leptin levels than men (21.9 ± 13.3 ng/ml versus 8.0 ± 6.6 ng/ml respectively; P < 0.0001). Both obese men and women bearing at least one T allele had increased plasma leptin levels as compared with their obese CC counterparts (19.6 ± 9.1 ng/ml for CT+TT versus 16.5 ± 8.5 ng/ml for CC in men; P < 0.016; 45.7 ± 13.1 ng/ml for CT+TT versus 38.0 ± 11.6 ng/ml for CC in women; P < 0.015).
Figure
DISCUSSION
In a representative sample of a northern French population the frequencies of the C and T alleles of the C/T exon 6 PPAR[gamma] polymorphism were 0.867 and 0.133 respectively. These frequencies were similar in obese (BMI > 30 kg/m2) and non-obese subjects. In obese subjects, however, plasma leptin levels of T allele bearers were 33% higher than those of CC homozygotes. Although levels of circulating leptin are higher in women than in men, this effect was similar in both genders. The plasma leptin level increase observed in obese T allele bearers was not associated with a concomitant elevation of body mass index, despite the high correlation between these two parameters, resulting in a greater leptin:BMI ratio in these subjects. These results show that variability within the PPAR[gamma] gene locus in obese subjects is associated with circulating leptin levels and may modify the relationships between leptin levels and adipose tissue mass.
The association between the C/T PPAR[gamma] polymorphism and serum leptin levels was detected in obese subjects only. Similar gene-environment interactions were previously described in population-based association studies involving other genes (24,25). For instance, triglyceride levels are elevated in obese individuals carrying the apolipoprotein E [epsis]4 allele (26). Moreover, the association between the PPAR[gamma] polymorphism and plasma leptin levels was consistent in both obese men and women carrying the T allele, despite the fact that women had at least a 2-fold higher leptin concentration than men. This suggests that the relationship was not dependent on the leptin concentration but was linked to elevation of body mass index. These results may correspond to gene-environment interactions occurring between the PPAR[gamma] gene and environmental factors associated with obesity.
In obese T allele bearers the observed increase in leptin levels was not associated with an increase in BMI, body weight or waist:hip ratio, resulting in a higher leptin:BMI ratio than in obese non-bearers. Thus for a given leptin level the BMI was relatively lower in obese T allele carriers than in obese CC homozygotes. Therefore, it appears that the T allele of the C/T exon 6 PPAR[gamma] polymorphism may confer an advantage because overweight subjects carrying the T allele are less obese than would be expected from their plasma leptin levels. Overall, this finding may suggest that the association between leptin level and adipose tissue mass may be modulated by a mutation in linkage disequilibrium with the C/T exon 6 PPAR[gamma] polymorphism.
Little is known about the factors that regulate circulating leptin levels. An earlier genetic study looked for genes involved in quantitative variation of leptin levels in Mexican Americans (27). In this study a candidate locus on chromosome 2 (but not on chromosome 3, where the PPAR[gamma] gene is located) was associated with leptin level variability. Several hypotheses may explain the lack of association between genetic markers on chromosome 3 and circulating leptin levels in the latter study. Firstly, the markers used in the analysis were spaced an average of 20 cM apart, which may be too large to detect a linkage disequilibrium on chromosome 3. Secondly, the distribution of genetic polymorphisms differs substantially between Mexican Americans and European Caucasians. Therefore, it is conceivable that some mutations may not exist in Mexican Americans but only in Caucasians. Finally, since the effect reported in our study was not found in the whole population but only in the obese subjects, the linkage might be undetectable in the whole population.
Experimental evidence suggests that PPAR[gamma] has a direct effect on leptin gene transcription. For instance, in animal models as well as in cell culture studies the pharmacological activation of PPAR[gamma] by thiazolidinediones results in down-regulation of leptin gene expression (11-14). These findings have not yet been demonstrated in humans (28). In our study the association between the C/T PPAR[gamma] polymorphism and circulating leptin levels in obese subjects could support these experimental observations. However, since the C/T exon 6 polymorphism is silent, this suggests that this polymorphism is in linkage disequilibrium with a functional mutation in the PPAR[gamma] locus or in a nearby genetic locus.
In conclusion, we report in obese subjects a significant association between a C/T exon 6 polymorphism of the PPAR[gamma] transcription factor and circulating leptin levels. Indeed, obese subjects bearing at least one T allele (CT+TT) had higher plasma leptin levels than subjects who did not (CC). This circulating leptin level increase was not associated with elevation of body mass index. These findings suggest that in obese subjects variability within the PPAR[gamma] gene locus is associated with circulating leptin levels and may modify the relationship between leptin level and adipose tissue mass. Further epidemiological and genetic studies, particularly family and association studies, of the PPAR[gamma] gene locus and nearby polymorphisms are needed to improve our understanding of the complex regulatory mechanisms governing leptin expression by adipocytes and their importance in obesity.
MATERIALS AND METHODS
Population study
Within the framework of the WHO MONICA (Multinational MONItoring of trends and determinants of CArdiovascular diseases; 29,30) Project in 1995-1996 we constituted a representative sample of 1195 men (n = 601) and women (n = 594) living in the urban community of Lille (northern France), aged 35-65 years. This study was randomly sampled from the electoral rolls and stratified on gender and 10 year age groups (overall response 70%). This study was approved by the Ethics Committee of the Centre Hospitalier et Universitaire de Lille. Each individual signed an informed consent. A detailed questionnaire was filled out including alcohol consumption and smoking estimations and personal medical history. BMI, waist:hip ratio and blood pressure were measured. A blood sample was drawn after a 10 h fast from 1170 participants (590 men, 580 women).
Biological measurements
Glucose was measured by the glucose oxidase method (DuPont Dimension). Plasma insulin was measured by radioimmunoassay (BiInsuline, ERIA Pasteur). Serum total cholesterol and triglyceride levels were measured by enzymatic methods (DuPont Dimension). Plasma leptin levels were measured by radioimmunoassay (Human Leptin RIA Kit, Wak-Chemie Medical GmBH, Germany).
Genetic analysis
Genomic DNA was extracted from white blood cells as previously described (31). DNA amplification was performed using the polymerase chain reaction (PCR) for 1154 subjects (25 refused blood sampling; 16 could not be genotyped for technical reasons). The primers used to amplify part of exon 6 of the PPAR[gamma] gene were derived from the genomic sequence of the PPAR[gamma] locus (16) and use of these primers gave a PCR product of 200 bp. The C/T exon 6 PPAR[gamma] polymorphism was detected using PmlI digestion followed by 3% agarose gel electrophoresis. To achieve this, 10 µl PCR product was digested by 2 U restriction endonuclease PmlI (New England Biolabs, Ozyme, France) with incubation buffer + 1% BSA in a total volume of 12 µl at 37°C overnight, giving two fragments of 120 and 80 bp. The most common allele has a C at nt 161, while the variant allele has a T at this position.
Statistical analysis
Complete results were obtained for 1154 subjects. Statistical analyses were performed with the SAS statistical software, v.6.11 (SAS Institute Inc., Cary, NC). Obesity was defined according to the WHO criteria (BMI > 30 kg/m2) (23). A body builder with a BMI of 30.8 kg/m2 was excluded from this group. Genotypic and allelic distributions according to gender and BMI subgroup were compared with Pearson [chi]2 statistical tests. The effect of the C/T exon 6 PPAR[gamma] polymorphism on quantitative variables was tested with a multivariate analysis of covariance using a general linear model. Because of interference by diseases and therapeutic treatments with blood variables, diabetic subjects and individuals under hypocholesterolemic and hypotensive treatment were excluded from these analyses (n = 334). The C/T exon 6 PPAR[gamma] genotype was introduced as a dichotomous variable in the analyses: subjects carrying at least one T allele versus subjects carrying no T allele. Interactions between genotypes and covariates were tested. Data for triglycerides, insulin, glucose and leptin were log transformed to normalize their distributions. Statistical significance was considered at the P < 0.05 level and Bonferroni approximation for multiple comparisons was used.
ABBREVIATIONS
PPAR[gamma], peroxisome proliferator-activated receptor [gamma]; BMI, body mass index (weight, kg/height, m2).
ACKNOWLEDGEMENTS
Mrs Aline Meirhaeghe was supported by a grant from the Ministère de l'Enseignement Supérieur et de la Recherche. The WHO-MONICA population study developed in the north of France was supported by grants from the Conseil Régional du Nord-Pas de Calais, ONIVINS, Parke-Davis Laboratory, Mutuelle Générale de l'Education Nationale (MGEN), the Réseau National de Santé Publique, the Direction Générale de La Santé, the Institut National de la Santé et de la Recherche Médicale (INSERM), the Institut Pasteur de Lille and the Unité d'Evaluation du Centre Hospitalier et Universitaire de Lille.
REFERENCES
*To whom correspondence should be addressed. Tel: +33 3 20 87 77 10; Fax: +33 3 20 87 78 94; Email: philippe.amouyel@pasteur-lille.fr
This page is run by Oxford University Press, Great Clarendon Street, Oxford OX2 6DP, as part of the OUP Journals
Comments and feedback: www-admin{at}oup.co.uk
Last modification: 14 Feb 1998
Copyright© Oxford University Press, 1998.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. E Cecil, C. N. Palmer, B. Fischer, P. Watt, D. J Wallis, I. Murrie, and M. M Hetherington Variants of the peroxisome proliferator-activated receptor {gamma}- and {beta}-adrenergic receptor genes are associated with measures of compensatory eating behaviors in young children Am. J. Clinical Nutrition, July 1, 2007; 86(1): 167 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kiyomizu, J. Kitawaki, H. Obayashi, M. Ohta, H. Koshiba, H. Ishihara, and H. Honjo Association of Two Polymorphisms in the Peroxisome Proliferator-Acativated Receptor-{gamma} Gene With Adenomyosis, Endometriosis, and Leiomyomata in Japanese Women Reproductive Sciences, July 1, 2006; 13(5): 372 - 377. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Meirhaeghe, D. Cottel, P. Amouyel, and J. Dallongeville Association Between Peroxisome Proliferator-Activated Receptor {gamma} Haplotypes and the Metabolic Syndrome in French Men and Women Diabetes, October 1, 2005; 54(10): 3043 - 3048. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Paracchini, P. Pedotti, and E. Taioli Genetics of Leptin and Obesity: A HuGE Review Am. J. Epidemiol., July 15, 2005; 162(2): 101 - 114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Knouff and J. Auwerx Peroxisome Proliferator-Activated Receptor-{gamma} Calls for Activation in Moderation: Lessons from Genetics and Pharmacology Endocr. Rev., December 1, 2004; 25(6): 899 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S.F. Doney, B. Fischer, G. Leese, A. D. Morris, and C. N.A. Palmer Cardiovascular Risk in Type 2 Diabetes Is Associated With Variation at the PPARG Locus: A Go-DARTS Study Arterioscler Thromb Vasc Biol, December 1, 2004; 24(12): 2403 - 2407. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E J Parra, C J Hoggart, C Bonilla, S Dios, J M Norris, J A Marshall, R F Hamman, R E Ferrell, P M McKeigue, and M D Shriver Relation of type 2 diabetes to individual admixture and candidate gene polymorphisms in the Hispanic American population of San Luis Valley, Colorado J. Med. Genet., November 1, 2004; 41(11): e116 - e116. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Z. Al-Shali, A. A. House, A. J.G. Hanley, H. M.R. Khan, S. B. Harris, B. Zinman, M. Mamakeesick, A. Fenster, J. D. Spence, and R. A. Hegele Genetic Variation in PPARG Encoding Peroxisome Proliferator-Activated Receptor {gamma} Associated With Carotid Atherosclerosis Stroke, September 1, 2004; 35(9): 2036 - 2040. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Tai, D. Corella, M. Deurenberg-Yap, X. Adiconis, S. K. Chew, C. E. Tan, and J. M. Ordovas Differential effects of the C1431T and Pro12Ala PPAR{gamma} gene variants on plasma lipids and diabetes risk in an Asian population J. Lipid Res., April 1, 2004; 45(4): 674 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Orio Jr., G. Matarese, S. Di Biase, S. Palomba, D. Labella, V. Sanna, S. Savastano, F. Zullo, A. Colao, and G. Lombardi Exon 6 and 2 Peroxisome Proliferator-Activated Receptor-{gamma} Polymorphisms in Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5887 - 5892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Herbst, L. R. Tannock, S. S. Deeb, J. Q. Purnell, J. D. Brunzell, and A. Chait Kobberling Type of Familial Partial Lipodystrophy: An underrecognized syndrome Diabetes Care, June 1, 2003; 26(6): 1819 - 1824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Meirhaeghe, L. Fajas, F. Gouilleux, D. Cottel, N. Helbecque, J. Auwerx, and P. Amouyel A Functional Polymorphism in a STAT5B Site of the Human PPAR{gamma}3 Gene Promoter Affects Height and Lipid Metabolism in a French Population Arterioscler Thromb Vasc Biol, February 1, 2003; 23(2): 289 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Stumvoll and H. Haring The Peroxisome Proliferator-Activated Receptor-{gamma}2 Pro12Ala Polymorphism Diabetes, August 1, 2002; 51(8): 2341 - 2347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Stefan, A. Fritsche, H. Häring, and M. Stumvoll Effect of Experimental Elevation of Free Fatty Acids on Insulin Secretion and Insulin Sensitivity in Healthy Carriers of the Pro12Ala Polymorphism of the Peroxisome Proliferator-Activated Receptor-{gamma}2 Gene Diabetes, May 1, 2001; 50(5): 1143 - 1148. [Abstract] [Full Text]
|
|
|
|
|
|
M. Stumvoll, H. G. Wahl, K. Löblein, R. Becker, F. Machicao, S. Jacob, and H. Häring Pro12Ala Polymorphism in the Peroxisome Proliferator-Activated Receptor-{gamma}2 Gene Is Associated With Increased Antilipolytic Insulin Sensitivity Diabetes, April 1, 2001; 50(4): 876 - 881. [Abstract] [Full Text]
|
|
|
|
|
|
W.-C. Hsueh, B. D. Mitchell, J. L. Schneider, P. L. St. Jean, T. I. Pollin, M. G. Ehm, M. J. Wagner, D. K. Burns, H. Sakul, C. J. Bell, et al. Genome-Wide Scan of Obesity in the Old Order Amish J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1199 - 1205. [Abstract] [Full Text]
|
|
|
|
|
|
S. J. Hasstedt, Q.-F. Ren, K. Teng, and S. C. Elbein Effect of the Peroxisome Proliferator-Activated Receptor-{{gamma}}2 Pro12Ala Variant on Obesity, Glucose Homeostasis, and Blood Pressure in Members of Familial Type 2 Diabetic Kindreds J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 536 - 541. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. A. HEGELE, H. CAO, S. B. HARRIS, B. ZINMAN, A. J. HANLEY, and C. M. ANDERSON Genetic variation in LMNA modulates plasma leptin and indices of obesity in aboriginal Canadians Physiol Genomics, June 29, 2000; 3(1): 39 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-P. Zhou, W. M Smith, O. Gimm, E. Mueller, X. Gao, P. Sarraf, T. W Prior, C. Plass, A. von Deimling, P. M. Black, et al. Over-representation of PPARgamma sequence variants in sporadic cases of glioblastoma multiforme: preliminary evidence for common low penetrance modifiers for brain tumour risk in the general population J. Med. Genet., June 1, 2000; 37(6): 410 - 414. [Abstract] [Full Text]
|
|
|
|
|
|
F. Krempler, D. Breban, H. Oberkofler, H. Esterbauer, E. Hell, B. Paulweber, and W. Patsch Leptin, Peroxisome Proliferator-Activated Receptor-{gamma}, and CCAAT/Enhancer Binding Protein-{alpha} mRNA Expression in Adipose Tissue of Humans and Their Relation to Cardiovascular Risk Factors Arterioscler Thromb Vasc Biol, February 1, 2000; 20(2): 443 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Knoblauch, A. Busjahn, B. Muller-Myhsok, H.-D. Faulhaber, H. Schuster, R. Uhlmann, and F. C. Luft Peroxisome Proliferator-Activated Receptor {gamma} Gene Locus Is Related to Body Mass Index and Lipid Values in Healthy Nonobese Subjects Arterioscler Thromb Vasc Biol, December 1, 1999; 19(12): 2940 - 2944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. L. Wang, J. Oosterhof, and N. Duarte Peroxisome proliferator-activated receptor {gamma} C161->T polymorphism and coronary artery disease Cardiovasc Res, December 1, 1999; 44(3): 588 - 594. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Valve, K. Sivenius, R. Miettinen, J. Pihlajamaki, A. Rissanen, S. S. Deeb, J. Auwerx, M. Uusitupa, and M. Laakso Two Polymorphisms in the Peroxisome Proliferator-Activated Receptor-{gamma} Gene Are Associated with Severe Overweight among Obese Women J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3708 - 3712. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||